Media headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stemline Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5555970753879 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN (nasdaq.com)
- Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment (finance.yahoo.com)
- Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented (markets.financialcontent.com)
- Analysts suggested mean rating score of 1.50 for Stemline Therapeutics, Inc. (STML) – Wall Street Morning (wallstreetmorning.com)
- Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting – Nasdaq (nasdaq.com)
Several research firms recently commented on STML. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. BidaskClub lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $33.75.
Stemline Therapeutics (NASDAQ:STML) opened at $15.65 on Thursday. Stemline Therapeutics has a one year low of $5.50 and a one year high of $16.00.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/12/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-stemline-therapeutics-stml-stock-price.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.